Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › STEP 9

STEP 9

Semaglutide · Knee osteoarthritis + obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Semaglutide
Population
Knee osteoarthritis + obesity
Official title
Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
Sponsor
Novo Nordisk A/S
Phase
Phase 3
Registry status
completed · 2021-10 → 2023-07
Participants
407
Duration
68 weeks
Registry
NCT05064735

Outcomes in the indication

STEP 9 Semaglutide · Knee osteoarthritis + obesity · 68 weeks · n = 407 seed

WOMAC pain −41.7 vs −27.5 points; weight −13.7 % vs −3.2 %

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: STEP 9. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/step-9/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.